Midostaurin, sold under the brand name Rydapt by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. |
Read full article at Wikipedia
|
InChI=1S/C35H30N4O4/c1- 35- 32(42- 3) 25(37(2) 34(41) 19- 11- 5- 4- 6- 12- 19) 17- 26(43- 35) 38- 23- 15- 9- 7- 13- 20(23) 28- 29- 22(18- 36- 33(29) 40) 27- 21- 14- 8- 10- 16- 24(21) 39(35) 31(27) 30(28) 38/h4- 16,25- 26,32H,17- 18H2,1- 3H3,(H,36,40) /t25- ,26- ,32- ,35+/m1/s1 |
BMGQWWVMWDBQGC-IIFHNQTCSA-N |
CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1 |
|
EC 2.7.11.13 (protein kinase C) inhibitor
An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13).
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
N- [(5S,6R,7R,9R)- 6- methoxy- 5- methyl- 14- oxo- 6,7,8,9,15,16- hexahydro- 5H,14H- 5,9- epoxy- 4b,9a,15- triazadibenzo[b,h]cyclonona[1,2,3,4- jkl]cyclopenta[e]- as- indacen- 7- yl]- N- methylbenzamide
|
4'-N-benzoylstaurosporine
|
ChemIDplus
|
benzoylstaurosporine
|
ChemIDplus
|
CGP 41251
|
ChemIDplus
|
CGP-41251
|
ChemIDplus
|
PKC 412
|
ChemIDplus
|
PKC412
|
ChemIDplus
|
120685-11-2
|
CAS Registry Number
|
ChemIDplus
|
7345336
|
Reaxys Registry Number
|
Reaxys
|
20980353
|
PubMed citation
|
Europe PMC
|
|